Evidence map›Paper›PMID 42755871›Full record

ArticleFrontiers in oncology2026

Interpretable machine learning for prediction of leptomeningeal metastasis in lung adenocarcinoma: a multi-centre retrospective study via "Prompt" model.

Xinyang Li, Jingxiang Su, Yitao Fan, Yingda Xie, Hongyan Liu, Tingting Wei, Ruoyu Yao, Renke Yu, Lu Zheng, Bo Sun and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xinyang Li *Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Jingxiang Su *Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
Yitao Fan *Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Yingda XieHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Hongyan LiuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Tingting WeiHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Ruoyu YaoHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Renke YuDepartment of General Practice, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lu ZhengDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
Bo SunHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Xiangjun QiuCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Jiachun SunHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leptomeningeal metastasis (LM) is a serious complication of lung adenocarcinoma (LUAD). Owing to the difficulty in early diagnosis and the limited clinical benefit of available treatments, affected patients experience extremely poor outcomes. Thus, the machine-learning-enhanced predictive framework Prompt was developed to optimise early clinical identification and prognostic assessment. This model was designed to determine major risk factors for LM in patients with LUAD, estimate the possibility of LM onset and predict survival, thereby supporting clinical decision-making via an early-warning system and accurate survival prediction. Methods: Clinical data of patients diagnosed with LUAD complicated by LM (LUAD-LM) between 1 January 2012 and 1 January 2025 were obtained from electronic medical databases across multiple medical centres. Embedded feature selection was conducted using tree-based feature importance ranking. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) to determine the most suitable machine-learning model. Shapley additive explanation (SHAP) values were applied to interpret the high-risk diagnostic model, and survival outcomes were examined using Cox proportional hazards regression. Results: Among 6,784 screened LUAD cases, 181 individuals met the inclusion criteria for patients with confirmed LUAD-LM. A high-risk diagnostic model for LUAD-LM was developed using the Tabular Prior-data Fitted Network (TabPFN), an approach recently published in Conclusion: Prompt framework delivers exploratory LM risk and survival estimations for Chinese patients with LUAD, serving as a preliminary risk-stratification reference rather than a universally applicable clinical diagnostic tool pending prospective external validation across diverse populations and healthcare systems.

Indexed as

leptomeningeal metastasislung cancerpredictive modelSHAPStreamlitTabular Prior-data Fitted Network (TabPFN)

Identifiers

PMID42755871
PMCPMC13581907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.